Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets

Blood

Volumn 91, Issue 5, 1998, Pages 1572-1581

  Hillery, Cheryl A ^a   Mancuso, David J ^b   Sadler, J Evan ^b   Ponder, Jay W ^b   Jozwiak, Mary A ^b   Christopherson, Pamela A ^b   Gill, Joan Cox ^b   Scott, J Paul ^b   Montgomery, Robert R ^b  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 3; DESMOPRESSIN; DNA; MONOCLONAL ANTIBODY; VON WILLEBRAND FACTOR;

AMINO ACID SUBSTITUTION; ARTICLE; BLEEDING DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EPISTAXIS; FEMALE; GENETIC DISORDER; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; PEDIGREE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE;

EID: 0032032301     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.5.1572     Document Type: Article

References (50)

1. Montgomery RR, Coller BS: von Willebrand Disease, in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA, Lippincott, 1994, p 134
2. Mayadas TN, Wagner DD: von Willebrand factor biosynthesis and processing. Ann N Y Acad Sci 614:153, 1991
3. Santoro SA: Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res 21:689, 1981
4. Weiss HJ: von Willebrand factor and platelet function. Ann N Y Acad Sci 614:125, 1991
5. Ruggeri ZM, De Marco L, Gatti L, Bader R, Montgomery RR: Platelets have more than one binding site for von Willebrand factor. J Clin Invest 72:1, 1983
6. Nachman RL, Jaffe EA, Weksler BB: Immunoinhibition of ristocetin-induced platelet aggregation. J Clin Invest 59:143, 1977
7. Fujimura Y, Holland LZ, Ruggeri ZM, Zimmerman TS: The von Willebrand factor domain-mediating botrocetin-induced binding to glycoprotein IB lies between Val449 and Lys728. Blood 70:985, 1987
8. Fujimura Y, Titani K, Holland LZ, Russell SR, Roberts JR, Elder JH, Ruggeri ZM, Zimmerman TS: von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 261:381, 1986
9. Andrews RK, Gorman JJ, Booth WJ, Corino GL, Castaldi PA, Berndt MC: Cross-linking of a monomeric 39/34-kDa dispase fragment of von Willebrand factor (Leu-480/Val-481-Gly-718) to the N-terminal region of the alpha-chain of membrane glycoprotein Ib on intact platelets with bis(sulfosuccinimidyl) suberate. Biochemistry 28:8326, 1989
10. Marti T, Rosselet SJ, Titani K, Walsh KA: Identification of disulfide-bridged substructures within human von Willebrand factor. Biochemistry 26:8099, 1987
11. Sadler JE: A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 71:520, 1994
12. Ruggeri ZM: Structure and function of von Willebrand factor: Relationship to von Willebrand's disease. Mayo Clin Proc 66:847, 1991
13. Mancuso DJ, Kroner PA, Christopherson PA, Vokac EA, Gill JC, Montgomery RR, Gill, JC: Type 2M:Milwaukee-1 von Willebrand disease: An in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets. Blood 88:2559, 1996
14. Rabinowitz I, Tuley EA, Mancuso DJ, Randi AM, Firkin BG, Howard MA, Sadler JE: von Willebrand disease type B: A missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc Natl Acad Sci USA 89:9846, 1992
15. Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS: Serial studies in von Willebrand's disease: Variability versus "variants". Blood 56:712, 1980
16. Zimmerman TS, Hoyer LW, Dickson L, Edgington TS: Determination of the von Willebrand's disease antigen (factor VIII-related antigen) in plasma by quantitative immunoelectrophoresis. J Lab Clin Med 86:152, 1975
17. Ruggeri ZM, Zimmerman TS: Variant von Willebrand's disease: Characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 65:1318, 1980
18. Ruggeri ZM, Zimmerman TS: The complex multimeric composition of factor VIII/von Willebrand factor. Blood 57:1140, 1981
19. Kroner PA, Kluessendorf ML, Scott JP, Montgomery RR: Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets. Blood 79:2048, 1992
20. Bonthron D, Orr EC, Mitsock LM, Ginsburg D, Handin RI, Orkin SH: Nucleotide sequence of pre-pro-von Willebrand factor cDNA. Nucleic Acids Res 14:7125, 1986
21. Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton-Inloes BB, Sorace JM, Alevy YG, Sadler JE: Structure of the gene for human von Willebrand factor. J Biol Chem 264:19514, 1989
22. Mancuso DJ, Tuley EA, Westfield LA, Lester-Mancuso TL, Le Beau MM, Sorace JM, Sadler JE: Human von Willebrand factor gene and pseudogene: Structural analysis and differentiation by polymerase chain reaction. Biochemistry 30:253, 1991
23. Feigner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielson M: Lipofection: A highly efficient, lipid-mediated DNA transfection procedure. Proc Natl Acad Sci USA 84:7413, 1987
24. Montgomery RR, Kunicki TJ, Glode LM: Use of monoclonal antibody to increase the sensitivity and specificity of precipitating immunoassays and cell surface binding immunoassays. Methods Enzymol 121:702, 1986
25. Raines G, Aumann H, Sykes S, Street A: Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res 60:201, 1990
26. Scott JP, Montgomery RR: The rapid differentiation of type IIb von Willebrand disease from platelet-type (pseudo-) von Willebrand disease by the "neutral" monoclonal antibody binding assay. Am J Clin Pathol 96:723, 1991
27. Schullek J, Jordan J, Montgomery RR: Interaction of von Willebrand factor with human platelets in the plasma milieu. J Clin Invest 73:421, 1984
28. Andrews RK, Booth WJ, Gorman JJ, Castaldi PA, Berndt MC: Purification of botrocetin from Bothrops jararaca venom. Analysis of the botrocetin-mediated interaction between von Willebrand factor and the human platelet membrane glycoprotein Ib-IX complex. Biochemistry 28:8317, 1989
29. Kawai Y, Montgomery RR: Endothelial cell processing of von Willebrand proteins. Ann N Y Acad Sci 509:60, 1987
30. Lee JO, Rieu P, Amaout MA, Liddington R: Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell 80:631, 1995
31. Qu A, Leahy DJ: Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, alpha L beta 2) integrin. Proc Natl Acad Sci USA 92:10277, 1995
32. Bowie JU, Luthy R, Eisenberg D: A method to identify protein sequences that fold into a known three-dimensional structure. Science 253:164, 1991
33. Dudek MJ, Ponder JW: Accurate modeling of the intramolecular electrostatic energy of proteins. J Comp Chem 16:791, 1995
34. Vriend G: WHAT IF: A molecular modeling and drug design program. J Mol Graph 8:52, 1990
35. Vriend G, Sander C: Detection of common three-dimensional substructures in proteins. Proteins 11:52, 1991
36. Vriend G, Sander C: Quality control of protein models: Directional atomic contact analysis. J Appl Cryst 26:47, 1993
37. Ruggeri ZM, Ware J: The structure and function of von Willebrand factor. Thromb Haemost 67:594, 1992
38. Sadler JE: von Willebrand factor. J Biol Chem 266:22777, 1991
39. Berndt MC, Ward CM, Booth WJ, Castaldi PA, Mazurov AV, Andrews RK: Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin. Biochemistry 31:11144, 1992
40. Sadler JE, Ginsburg D: A database of polymorphisms in the von Willebrand factor gene and pseudogene. Thromb Haemost 69:185, 1993
41. Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RJ: Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen binding site by analysis of recombinant vWF a domain polypeptides. J Biol Chem 270:10822, 1995
42. Denis C, Baruch D, Kielty CM, Ajzenberg N, Christophe O, Meyer D: Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen. Arterioscler Thromb 13:398, 1993
43. Meyer D, Fressinaud E, Gaucher C, Lavergne JM, Hubert L, Ribba AS, Jorieux S, Mazurier C, the INSERM Network on Molecular Abnormalities in von Willebrand Disease: Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: From the patient to the gene. Thromb Haemost 78:451, 1997
44. Brandeen CI: Relation between structure and function of alpha/beta-proteins. Q Rev Biophys 13:317, 1980
45. Celikel R, Varughese KI, Madhusudan A, Yoshioka A, Ware J, Ruggeri ZM: Crystal structure of von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Thromb Haemost 769:HI-9, 1997 (abstr)
46. Ginsburg D, Sadler JE: von Willebrand disease: A database of point mutations, insertions, and deletions. For the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 69:177, 1993
47. Sugimoto M, Mohri H, McClintock RA, Ruggeri ZM: Identification of discontinuous von Willebrand factor sequences involved in complex formation with botrocetin. A model for the regulation of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 266:18172, 1991
48. Matsushita T, Sadler JE: Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem 270:13406, 1995
49. Kroner PA, Frey AB: Analysis of the structure and function of the von Willebrand factor A1 domain using targeted deletions and alanine-scanning mutagenesis. Biochemistry 35:13460, 1996
50. Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D: Ristocetin and Botrocetin involve two distinct domains of von Willebrand Factor for binding to platelet membrane glycoprotein Ib. Thromb Haemost 64:326, 1990